内科理论与实践2025，Vol.20Issue(6)：487-489,3.DOI:10.16138/j.1673-6087.2025.06.10
罗沙司他致血液透析患者中枢性甲状腺功能减退2例
Roxadustat-induced central hypothyroidism in hemodialysis patients:a report of two cases
摘要
Abstract
Hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI)is a novel class of oral medications for treating renal anemia,but adverse drug events have been reported both in China and internationally in recent years.This article reports two cases of reversible central hypothyroidism following the administration of the HIF-PHI roxadustat in patients undergoing regular hemodialysis with end-stage renal disease.Both patients gradually developed non-specific discomfort symptoms after one year of oral roxadustat treatment.Laboratory tests revealed abnormal thyroid function,while cranial magnetic resonance imaging showed no abnormalities.After discontinuation of roxadustat,thyroid function returned to normal and the symptoms resolved.These two cases suggest that it is necessary to monitor thyroid function in patients receiving oral roxadustat for renal anemia.关键词
低氧诱导因子脯氨酸羟化酶抑制剂/罗沙司他/中枢性甲状腺功能减退/血液透析/肾性贫血Key words
Hypoxia-inducible factor prolyl hydroxylase inhibitor/Roxadustat/Central hypothyroidism/Hemodialysis/Renal anemia分类
医药卫生引用本文复制引用
夏宇苗,傅鹏,吴灏..罗沙司他致血液透析患者中枢性甲状腺功能减退2例[J].内科理论与实践,2025,20(6):487-489,3.基金项目
上海市长宁区医疗卫生科研专项课题(CNKW2022Y06) （CNKW2022Y06）
